Psoriatic Arthritis

New recommendations from the National Psoriasis Foundation offer answers. The express goal of these guidelines: to reduce disease severity through proper nutrition.

Two characteristics predict a worse response to biologics.

Two recent studies focus on the risks of osteoporosis and cardiovascular disease in patients on the psoriatic arthritis/psoriasis spectrum.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

Insights from digital patient communities on disease-related impairments that PRO tools may miss.

Real-world health claims data demonstrate an elevated risk of cardiovascular and autoimmune diseases.

Findings from the first study to compare the therapeutic response to corticosteroids in axial psoriatic arthritis and ankylosing spondylitis.

Among the hot topics at the 2018 British Society for Rheumatology Annual Conference: a novel radiographic scoring system and cardiovascular risk assessment based on PsA subtype.

Researchers look deep to find the cause of synovitis and dactylitis in patients with psoriatic arthritis.

Which came first: the psoriatic arthritis or the cardiovascular risk factors?

Are you up-to-date on the latest recommendations for PsA from EULAR and GRAPPA? Take our 6-question quiz to find out.

What's new: reliable outcome measures, overlap in treatment targets, and immune checkpoint inhibitors.

Findings from the first real-world study of gaps in care for hypertension and dyslipidemia in patients with psoriasis and psoriatic arthritis.

Various biologics that focus on the IL-17 pathway are currently being studied.

British investigators take a long-range view of tumor necrosis factor inhibitors in patients with psoriatic arthritis.

An expanded role for MRI and 2 recently approved treatment options.

New data highlight the role of the C5a-C5aR axis in the onset of inflammation.

Moderate to high disease activity may persist.

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.

Previously approved for moderate-to-severe rheumatoid arthritis, golimumab received 2 new indications.

The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.

Patients demonstrated improved disease response in 2 clinical trials.